Study population clinical and laboratory characteristics
| . | CLL . | Healthy . |
|---|---|---|
| Total no. of subjects* | 84 | 49 |
| Rai stage | ||
| 0-I | 54 | NA |
| II-IV | 21 | NA |
| IGHV mutation status | ||
| Mutated (≥ 2%) | 44 | NA |
| Unmutated (< 2%) | 35 | NA |
| CD38 status | ||
| Low (< 30%) | 45 | NA |
| High (≥ 30%) | 26 | NA |
| Age, y | ||
| Median | 65 | 59 |
| Range | 34-91 | 44-89 |
| . | CLL . | Healthy . |
|---|---|---|
| Total no. of subjects* | 84 | 49 |
| Rai stage | ||
| 0-I | 54 | NA |
| II-IV | 21 | NA |
| IGHV mutation status | ||
| Mutated (≥ 2%) | 44 | NA |
| Unmutated (< 2%) | 35 | NA |
| CD38 status | ||
| Low (< 30%) | 45 | NA |
| High (≥ 30%) | 26 | NA |
| Age, y | ||
| Median | 65 | 59 |
| Range | 34-91 | 44-89 |
NA indicates not applicable.
Clinical data were not available on all 84 CLL patients: Rai stage (75/84), IGHV mutation status (79/84), and CD38 percentages (71/84).